Real-world risk evaluation of remdesivir in patients with an estimated glomerular filtration rate of less than 30 mL/min

Am J Health Syst Pharm. 2021 Nov 23;78(23):2101-2102. doi: 10.1093/ajhp/zxab245.

Authors

Timothy J Schieber^{1

2}, Nicholas Bennett³, Laura Aragon³, Jeannette Ploetz², Sarah Boyd^{3

4}

Affiliations

¹ School of Pharmacy University of Missouri-Kansas City Kansas City, MO.
² Department of Pharmacy Saint Luke's Health System Kansas City, MO, USA.
³ Antimicrobial and Diagnostic Advisement Program Saint Luke's Health System Kansas City, MO, USA.
⁴ Division of Infectious Disease Department of Medicine Saint Luke's Health System Kansas City, MO, USA.

No abstract available

Keywords: COVID-19; coronavirus; dialysis; remdesivir; renal.

Publication types

Letter

MeSH terms

Adenosine Monophosphate / adverse effects
Adenosine Monophosphate / analogs & derivatives
Alanine* / adverse effects
Alanine* / analogs & derivatives
Antiviral Agents* / adverse effects
Glomerular Filtration Rate
Humans

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine